Evolus (EOLS) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Evolus (EOLS) over the past year, gaining 28.0% versus a gain of 25.6%. Over five years, XERS leads with a +424.0% price change compared with +1.7% for EOLS. Xeris Biopharma is the larger company by market cap ($1.91 billion vs $510.6 million), about 3.7 times the size.
On valuation, Evolus trades at a lower forward P/E (26.4x vs 28.3x for Xeris Biopharma).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | XERS |
|---|---|---|
| Share price | $7.73 | $10.48 |
| Market cap | $510.57M | $1.91B |
| 1-day change | -0.90% | +2.85% |
| YTD return | +17.29% | +33.50% |
| 1-year return | +25.60% | +27.96% |
| 5-year return | +1.69% | +424.00% |
| Forward P/E | 26.43 | 28.32 |
| EPS (TTM) | $-0.53 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $291.85M |
| Revenue growth (YoY) | — | +43.72% |
| Net income (latest FY) | — | $554.00K |
| Gross margin | — | 85.41% |
| Operating margin | — | 8.53% |
| Net margin | — | 0.19% |
| 52-week high | $9.31 | $11.33 |
| 52-week low | $3.86 | $5.25 |
| Distance from 52-week high | -16.97% | -7.50% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +94.05% | +22.71% |
| Average volume | 904.95K | 2.18M |
| Shares outstanding | 66.05M | 182.32M |
| Employees | 353 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Xeris Biopharma is about 3.7 times larger than Evolus by market value ($1.91B vs $510.57M).
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 353 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
EOLS vs XERS FAQ
Which is bigger, Evolus or Xeris Biopharma?
Xeris Biopharma (XERS) is larger, with a market capitalization of $1.91B compared with $510.57M for Evolus (EOLS).
Which stock has performed better over the past year, EOLS or XERS?
XERS returned +27.96% over the past 12 months, compared with +25.60% for EOLS (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.